Activase® (alteplase) is the standard of care for treating eligible patients with acute ischemic stroke (AIS) within 3 hours of symptom onset 2 

Review AHA/ASA stroke treatment guidelines

The American Heart Association/American Stroke Association (AHA/ASA) practice guidelines recommend Activase for treatment of AIS:

  • Intravenous Activase (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of ischemic stroke onset (Class 1; Level of Evidence A, 2013 AHA/ASA Guidelines) 2
  • The benefit of Activase therapy is time-dependent, and treatment should be initiated as quickly as possible in eligible patients. The door-to-needle (DTN) time (time of bolus administration) should be within 60 minutes of hospital arrival (Class 1; Level of Evidence A, 2013 AHA/ASA Guidelines) 2
  • To assess all patients with suspected AIS, immediate diagnostic tests which must be performed and included in the 2013 guidelines are 2:
    • Non-contrast brain CT or brain magnetic resonance imaging (MRI)
    • Blood glucose
    • Oxygen saturation